Axion BioSystems Introduces Synexus, Bringing Single-Cell Resolution to High-Throughput Functional Cell Analysis

Synexus functional cell analysis platform with Pixel HD technology

ATLANTA—[November 2, 2026]—Axion BioSystems, a leading provider of advanced live-cell analysis technology, today announced the launch of Synexus, a next-generation platform for disease research and therapeutic development. Synexus provides richer, more connected views of cell behavior to redefine how researchers investigate dynamic biological systems.

Synexus unites function and morphology on the same plate, bringing single-cell resolution to high-throughput, label-free workflows. Combining proven microelectrode array (MEA) technology, next-generation high-density MEA (HD-MEA), and groundbreaking electrical imaging, its expansive range of measurement modes allows scientists to select the capabilities at the scale and resolution best suited to each experiment, creating a platform that adapts as research evolves.

“Synexus represents the culmination of many years of significant investment in a next-generation platform and is a major step forward for Axion,” said Julien Bradley, CEO of Axion BioSystems. “We are extending our established leadership in MEA into high-definition electrophysiology and advanced spatial cell analysis. By bringing these capabilities together on a common platform, Synexus supports the applications our customers rely on today while creating new opportunities across emerging applications and markets.”

Designed for the next generation of live-cell research

As biotechnology research increasingly relies on complex human cell models and phenotypic assays, laboratories need technologies that can capture multiple dimensions of cellular biology without disrupting cells or sacrificing throughput. Synexus addresses this need.

Rather than operating as a fixed-purpose instrument, Synexus allows researchers to configure the system for the applications they need today, then add measurement capabilities, analysis modules, plate formats, and workflows as their research evolves. This approach helps laboratories protect their investment while giving Axion a common technology foundation for continued innovation.

Built on this common foundation, Synexus brings together:

  • High-throughput, label-free functional analysis, with simultaneous recording from up to 96 wells with 384-well coming soon.
  • Single-cell resolution, enabled by Pixel HD technology with more than 130,000 electrodes per well and 12.5 µm electrode spacing.
  • Application-specific workflows, supported by purpose-built software and consumables for neural, cardiac, and other live-cell analysis applications.

“Synexus gives researchers a way to connect functional activity with morphological change, providing a more complete picture of cellular behavior,” said Stacie Chvatal, Vice President of Product Management at Axion BioSystems. “By capturing both on the same plate, with the detail and throughput Synexus provides, researchers can uncover spatial heterogeneity and structure-function relationships that are difficult to see when measurements are separated across instruments or endpoints.”

Beyond MEA: Carrying a proven foundation into the next era of discovery

Synexus builds on more than 15 years of Axion BioSystems’ experience and an established live-cell analysis ecosystem that includes over 1500 systems installed worldwide and thousands of peer-reviewed publications using Axion technology. Its Maestro MEA technology has an established track record in pharmaceutical safety research, with widespread adoption among leading drug developers.

By extending this foundation into high-definition electrophysiology and electrical imaging, Synexus broadens the possibilities of label-free, functional cell analysis across neuroscience, cardiac research, drug discovery, safety pharmacology, disease modeling, and other applications that depend on noninvasive, real-time measurements from living cells.

Visit to learn more about Synexus.

Axion BioSystems Acquires High-Throughput, High-Density CMOS MEA Technology from CytoTronics

Axion BioSystems Acquires High-Throughput, High-Density CMOS MEA Technology from CytoTronics

ATLANTA, GA, January 22nd, 2026–(BUSINESS WIRE)–Axion BioSystems, a leading life sciences tools company focused on cutting-edge live-cell bioelectronic assay and imaging systems, announces the acquisition of the intellectual property and assets of CytoTronics, Inc.

The purchase brings novel high-density (HD) electrode array technology developed at Harvard University to Axion’s growing product suite and strengthens Axion’s ability to provide researchers with the most advanced tools for disease research and drug discovery.

Bioelectronic assays use biocompatible electronic microsensors embedded in the cell culture surface to continuously monitor living cells, detecting cell number, morphology, and even neural firing and cardiac beating without additional labels or dyes.

CytoTronics’ next-generation CMOS (Complementary Metal–Oxide–Semiconductor) microelectrode array (MEA) plates contain over 13 million nanoscale multimodal electrode-based sensors distributed across industry-standard 96- or 384-well microplates, enabling high-throughput screening for drug discovery at unprecedented single-cell resolution.

Co-founder and former Chief Executive Officer of CytoTronics, Inc., Jeffrey Abbott, PhD, now Vice President at Axion BioSystems, said: “Axion has a long-standing reputation for delivering intuitive, reliable, and scalable electrophysiology platforms to the cell biology community. That industry leadership makes Axion the ideal home for CytoTronics’ innovative technology. I’m excited to work with the Axion team to commercialize the next generation of high-throughput, high-density CMOS MEA assays for neural and cardiac drug discovery.”

“Since its founding in 2008, Axion’s goal has been to provide scientists with best-in-class tools to study electrically active cells like neurons and cardiomyocytes,” said Julien Bradley, Chief Executive Officer at Axion BioSystems. “The acquisition of CytoTronics’ technology is highly strategic for Axion, complementing our industry-leading MEA and impedance platforms with high-density arrays without sacrificing high throughput, and leveraging our high-performance software, robust hardware, and customer support infrastructure.”

 

About Axion BioSystems

Axion BioSystems is a leading life sciences tools company focused on innovative live-cell assays used to study the function of cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of new technologies that accelerate research and further the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and has offices in the Netherlands, the UK, and China.

www.axionbiosystems.com

CytoTronics Launches Neural Application for Pixel, Unleashing High-throughput Screening Capability in Drug Discovery for Neurological Disease

New system delivers multi-modal, live-cell high-throughput monitoring, pairs with laboratory automation to scale simultaneous single-cell resolution readouts to 100,000 wells cost effectively.

CytoTronics Secures $13.5M Series Seed 2 Financing to Speed Market Entry of Pixel System for Breakthroughs in Cell Biology

New system delivers multi-modal, live-cell high-throughput monitoring, pairs with laboratory automation to scale simultaneous single-cell resolution readouts to 100,000 wells cost effectively.

CytoTronics’ Pixel System Receives 2024 R&D 100 Award

CytoTronics is pleased to announce their flagship product, Pixel™, has been honored with a 2024 R&D 100 Award.

CytoTronics Breaks Scalability Barriers for Monitoring Live Cell Function, Reveals Pixel Octo for High-Throughput Cell Biology Discovery Applications 

New system delivers multi-modal, live-cell high-throughput monitoring, pairs with laboratory automation to scale simultaneous single-cell resolution readouts to 100,000 wells cost effectively.

Society for Laboratory Automation and Screening (SLAS) Selects CytoTronics’ Pixel System for 2024 New Product Award

CytoTronics honored for the North American debut of Pixel; opens enrollment for early access program.

CytoTronics Reveals Pixel System to Monitor Live Cell Function at an Unprecedented Scale for Cell Biology Applications

Breakthrough semiconductor-to-live-cell interface powered by microchips enables thousands of simultaneous, multi-modal readouts on any cell type at single-cell resolution.

CytoTronics’ Breakthrough Semiconductor Platform Poised to Set New Standard in High-Throughput Phenotypic Screening for Drug Discovery

Published data showcases the company’s potential to revolutionize pharmaceutical research.